Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy

86Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Disease relapse is a barrier to achieving therapeutic success after unrelated umbilical cord-blood transplantation (UCBT) for B-lineage acute lymphoblastic leukemia (B-ALL). While adoptive transfer of donor-derived tumor-specific T cells is a conceptually attractive approach to eliminating residual disease after allogeneic hematopoietic stem cell transplantation, adoptive immunotherapy after UCBT is constrained by the difficulty of generating antigen-specific T cells from functionally naive umbilical cord-blood (UCB)-derived T cells. Therefore, to generate T cells that recognize B-ALL, we have developed a chimeric immunoreceptor to redirect the specificity of T cells for CD19, a B-lineage antigen, and expressed this transgene in UCB-derived T cells. An ex vivo process, which is compliant with current good manufacturing practice for T-cell trials, has been developed to genetically modify and numerically expand UCB-derived T cells into CD19-specific effector cells. These are capable of CD19-restricted cytokine production and cytolysis in vitro, as well as mediating regression of CD19+ tumor and being selectively eliminated in vivo. Moreover, time-lapse microscopy of the genetically modified T-cell clones revealed an ability to lyse CD19+ tumor cells specifically and repetitively. These data provide the rationale for infusing UCB-derived CD19-specific T cells after UCBT to reduce the incidence of CD19+ B-ALL relapse. © 2006 by The American Society of Hematology.

References Powered by Scopus

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

2513Citations
N/AReaders
Get full text

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of t-cell clones from the donor

1640Citations
N/AReaders
Get full text

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors

1314Citations
N/AReaders
Get full text

Cited by Powered by Scopus

CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells

429Citations
N/AReaders
Get full text

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor

260Citations
N/AReaders
Get full text

Redirecting specificity of T-cell populations for CD19 using the sleeping beauty system

227Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Serrano, L. M., Pfeiffer, T., Olivares, S., Numbenjapon, T., Bennitt, J., Kim, D., … Cooper, L. J. N. (2006). Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood, 107(7), 2643–2652. https://doi.org/10.1182/blood-2005-09-3904

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

45%

Researcher 15

39%

Professor / Associate Prof. 4

11%

Lecturer / Post doc 2

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 21

55%

Agricultural and Biological Sciences 12

32%

Biochemistry, Genetics and Molecular Bi... 4

11%

Chemical Engineering 1

3%

Save time finding and organizing research with Mendeley

Sign up for free